Assessment of Serum Amylase pre and post Bariatric Surgery

Abstract

Background: Bariatric surgery is prevalent worldwide, including in Iraq. Morbid obesity, on the other hand, has become a global epidemic in the 20th century. Until now, bariatric surgery has been the only effective treatment  for  this  disease,  leading  to  sustained  weight  loss  and  the improvement of comorbidities. 
Aims of the study: To measure serum amylase pre and post bariatric surgery. 
Study design: This study is a case-control flow-up study. 
Method and Materials: We conducted the study in numerous obesity centers located in Mosul. The study commenced in December 2023 and concluded in May 2024. This study included 100 individual male and female who were over 18 years old, divided into two groups, 50 people control group BMI 18.5 – 24.9 kg/m2 and bariatric group BMI ≥ 40 kg/m , 
2
and were ready to undergo bariatric surgery. Serum amylase, if above 100 U/L, would indicate exocrine pancreatic insufficiency. 
Result: The  mean  serum  amylase  level  in  the  bariatric  group  (pre- operative)  compared  to  the  control  group  was  56.58±11.53  vs.  . 43.30±9.62  U/L  (P  =  0.0001),  and  between  two  independent  means bariatric  groups  (pre- and  post-surgery)  were  56.58±11.53  vs. 61.64±14.24 U/L (p-value = 0.001). 
Conclusions: In this study, 8% of the patients complained of increased serum amylase after surgery, and there was a risk of exocrine pancreatic insufficiency after sleeve surgery.